Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

被引：9

作者：

Bernard, Sophie ^{[1
]}

Ghesquieres, Herve ^{[2
]}

Casasnovas, Rene-Olivier ^{[3
]}

Griolet, Samuel ^{[4
]}

da Silva, Maria Gomes ^{[5
]}

Feugier, Pierre ^{[6
]}

Morschhauser, Franck ^{[7
]}

Trotman, Judith ^{[8
,9
]}

Renaud, Loic ^{[1
]}

Greil, Richard ^{[10
]}

Martin Garcia-Sancho, Alejandro ^{[11
]}

Grosicki, Sebastian ^{[12
]}

van Eygen, Koen ^{[13
]}

Copie-Bergman, Christiane ^{[14
]}

Haioun, Corinne ^{[15
]}

Thieblemont, Catherine ^{[1
,16
]}

机构：

[1] Hop St Louis, Assistance Publ Hop Paris, Hematooncol, Paris, France

[2] Hop Lyon, Hematol, Pierre Benite, France

[3] Ctr Hosp Univ Dijon, Serv Hematol Clin, INSERM, Unite Mixte Rech UMR 1231, Dijon, France

[4] Lymphoma Acad Res Org, Stat, Pierre Benite, France

[5] Inst Portuges Oncol, Lisbon, Portugal

[6] Univ Nancy, Ctr Hosp, Hematol, Nancy, France

[7] Univ Lille, Ctr Hosp Univ Lille, Hematol, Grp Rech Formes Injectables & Technol Assoc,EA 73, Lille, France

[8] Univ Sydney, Concord Repatriat Gen Hosp, Concord, NSW, Australia

[9] Univ Sydney, Concord, NSW, Australia

[10] Paracelsus Med Univ Salzburg, Ctr Clin Canc & Immunol Trials, Canc Cluster Salzburg, Salzburg Canc Res Inst, Salzburg, Austria

[11] Hosp Univ Salamanca, Salamanca, Spain

[12] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[13] Algemeen Ziekenhuis Groeninge Hosp, Campus Marias Voorzienigheid, Brugge, Belgium

[14] Univ Paris Est, INSERM U955, Henri Mondor Hosp, Assistance Publ Hop Paris,Dept Pathol, Creteil, France

[15] Hop Henri Mond, Assistance Publ Hop Paris, Unite Hemopathies Lymphoides, Creteil, France

[16] Univ Paris, NF KappaB, Differenciat & Canc, Paris, France

来源：

BLOOD ADVANCES | 2021年 / 5卷 / 15期

关键词：

B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; ELDERLY-PATIENTS; RISK-FACTORS; AGGRESSIVE LYMPHOMA; CNS PROPHYLAXIS; RITUXIMAB; MULTICENTER; IMPACT;

D O I：

10.1182/bloodadvances.2021004766

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2965 / 2968

页数：4

共 24 条

[1] Bernard S, 2018, HEMASPHERE, V2, P85
[2] Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516-The Southwest Oncology Group
Bernstein, Steven H.
Unger, Joseph M.
LeBlanc, Michael
Friedberg, Jonathan
Miller, Thomas P.
Fisher, Richard I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) : 114 - 119
[3] Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Boehme, V.
Zeynalova, S.
Kloess, M.
Loeffler, M.
Kaiser, U.
Pfreundschuh, M.
Schmitz, N.
[J]. ANNALS OF ONCOLOGY, 2007, 18 (01) : 149 - 157
[4] CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Boehme, Volkmar
Schmitz, Norbert
Zeynalova, Samira
Loeffler, Markus
Pfreundschuh, Michael
[J]. BLOOD, 2009, 113 (17) : 3896 - 3902
[5] A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
Cheah, C. Y.
Herbert, K. E.
O'Rourke, K.
Kennedy, G. A.
George, A.
Fedele, P. L.
Gilbertson, M.
Tan, S. Y.
Ritchie, D. S.
Opat, S. S.
Prince, H. M.
Dickinson, M.
Burbury, K.
Wolf, M.
Januszewicz, E. H.
Tam, C. S.
Westerman, D. A.
Carney, D. A.
Harrison, S. J.
Seymour, J. F.
[J]. BRITISH JOURNAL OF CANCER, 2014, 111 (06) : 1072 - 1079
[6] The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy
El-Galaly, Tarec Christoffer
Villa, Diego
Michaelsen, Thomas Yssing
Hutchings, Martin
Mikhaeel, Nabegh George
Savage, Kerry J.
Sehn, Laurie H.
Barrington, Sally
Hansen, Jakob W.
Smith, Daniel
Rady, Kirsty
Mylam, Karen J.
Larsen, Thomas S.
Holmberg, Staffan
Juul, Maja B.
Cordua, Sabrina
Clausen, Michael R.
Jensen, Kristina B.
Johnsen, Hans E.
Seymour, John F.
Connors, Joseph M.
Brown, Peter de Nully
Bogsted, Martin
Cheah, Chan Y.
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 195 - 203
[7] Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review
Eyre, Toby A.
Djebbari, Faouzi
Kirkwood, Amy A.
Collins, Graham P.
[J]. HAEMATOLOGICA, 2020, 105 (07) : 1914 - 1924
[8] Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era
Ferreri, Andres J. M.
Bruno-Ventre, Marta
Donadoni, Giovanni
Ponzoni, Maurilio
Citterio, Giovanni
Foppoli, Marco
Vignati, Alessandro
Scarfo, Lydia
Sassone, Marianna
Govi, Silvia
Caligaris-Cappio, Federico
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (05) : 654 - 662
[9] Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)
Ghesquieres, H.
Chevrier, M.
Laadhari, M.
Chinot, O.
Choquet, S.
Molucon-Chabrot, C.
Beauchesne, P.
Gressin, R.
Morschhauser, F.
Schmitt, A.
Gyan, E.
Hoang-Xuan, K.
Nicolas-Virelizier, E.
Cassoux, N.
Touitou, V
Le Garff-Tavernier, M.
Savignoni, A.
Turbiez, I
Soumelis, V
Houillier, C.
Soussain, C.
[J]. ANNALS OF ONCOLOGY, 2019, 30 (04) : 621 - 628
[10] Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
Gribben, John G.
Fowler, Nathan
Morschhauser, Franck
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2803 - U127

← 1 2 3 →